Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Net Income: 2011-2025

Historic Net Income for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$623,000.

  • Fennec Pharmaceuticals' Net Income rose 89.09% to -$623,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year decrease of 588.35%. This contributed to the annual value of -$436,000 for FY2024, which is 97.28% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Net Income is -$623,000, which was up 80.25% from -$3.2 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Net Income peaked at $12.9 million during Q1 2024, and registered a low of -$10.3 million during Q4 2022.
  • Its 3-year average for Net Income is -$1.9 million, with a median of -$2.6 million in 2023.
  • Data for Fennec Pharmaceuticals' Net Income shows a peak YoY increase of 316.58% (in 2024) and a maximum YoY decrease of 222.47% (in 2024) over the last 5 years.
  • Over the past 5 years, Fennec Pharmaceuticals' Net Income (Quarterly) stood at -$4.2 million in 2021, then tumbled by 89.66% to -$10.3 million in 2022, then surged by 74.66% to -$2.6 million in 2023, then soared by 42.67% to -$1.5 million in 2024, then skyrocketed by 89.09% to -$623,000 in 2025.
  • Its Net Income stands at -$623,000 for Q3 2025, versus -$3.2 million for Q2 2025 and -$1.2 million for Q1 2025.